# The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

> **NCT06861088** · PHASE3 · RECRUITING · sponsor: **Quercis Pharma AG** · enrollment: 480 (estimated)

## Conditions studied

- Venous Thromboembolism
- Metastatic Pancreatic Cancer
- Locally Advanced Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Kinisoquin™
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06861088
- **Lead sponsor:** Quercis Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-19
- **Primary completion:** 2027-10-31
- **Final completion:** 2029-10-31
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06861088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06861088, "The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06861088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*